Global Market Overview - The Hang Seng Index closed at 25,177, down 0.37% for the day but up 25.51% year-to-date [1] - The S&P 500 closed at 6,449, down 0.01% for the day and up 9.65% year-to-date [1] - The Shanghai Composite Index rose by 0.85% to 3,728, with a year-to-date increase of 11.23% [1] Industry Insights - The healthcare sector showed resilience, with major life sciences companies reporting better-than-expected performance in 2Q25, leading to upward revisions in annual guidance [5][6] - The pharmaceutical industry is facing pressure on profit margins due to external factors, but major pharmaceutical companies continue to invest in R&D, indicating a stable outlook for innovation [8] - The retail sector in the U.S. demonstrated resilience with a monthly growth rate increase from 0% in the first half of the year to 0.7% in July, indicating strong consumer spending [4] Company Analysis - Tongcheng Travel reported a total revenue of RMB 4.7 billion in 2Q25, a 10% year-on-year increase, with adjusted net profit rising by 18% to RMB 775 million, exceeding expectations [8] - Xtep's sales for the first half of 2025 grew by 7% to RMB 6.8 billion, with net profit increasing by 21% to RMB 913 million, surpassing forecasts [13] - Leap Motor achieved a revenue of RMB 14.2 billion in 2Q25, a 42% quarter-on-quarter increase, marking its first positive operating profit [14] Investment Ratings - Leap Motor is rated as a "Buy" with a target price of HKD 80, reflecting a strong growth outlook driven by new model launches and expanding sales [14] - Xtep maintains a "Buy" rating with a target price of HKD 7.39, supported by robust sales performance and operational efficiency [12] - Tongcheng Travel is also rated as a "Buy," with a target price of HKD 24.00, based on its strong core business performance [8]

Core Insights - BeiGene, Ltd. (百济神州) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] Financial Performance - As of June 30, 2025, BeiGene reported total revenue of $2.433 billion, representing a year-over-year growth of 44.73% [1] - The company's net profit attributable to shareholders was $95.59 million, showing a significant increase of 125.73% year-over-year [1] Product Portfolio - BeiGene has a comprehensive product portfolio that includes six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - The company has also obtained licenses for five drugs and investigational drugs, including three drugs (ABRAXANE, REVLIMID, and VIDAZA) exclusively licensed from Celgene that are already marketed in China, along with two investigational drugs in clinical stages [2] Company Background - Founded in Beijing in 2010, BeiGene was listed on the NASDAQ Global Select Market in February 2016 [2] - As of July 2018, the company had a global team of over 1,300 employees, showcasing its comprehensive capabilities in research, clinical development, manufacturing, and commercialization [2]

Group 1: Stock Recommendations - Geely Automobile is rated as a "Buy" with a target price of HKD 25.00, representing a potential upside of 25%[5] - Li Auto is rated as a "Buy" with a target price of HKD 72.00, indicating a potential upside of 7%[5] - Sany International is rated as a "Buy" with a target price of HKD 8.70, suggesting a potential upside of 22%[5] - Luckin Coffee is rated as a "Buy" with a target price of USD 44.95, indicating a potential upside of 17%[5] - Tencent is rated as a "Buy" with a target price of HKD 705.00, representing a potential upside of 19%[5] Group 2: Performance Overview - The basket of 26 long positions had an average return of 4.7%, compared to the MSCI China Index return of 5.2%[10] - Out of the 26 stocks, 11 stocks outperformed the benchmark[10] - The report includes a total of 26 stocks with varying sectors such as automotive, technology, and healthcare[5]

Core Insights - BeiGene, Ltd. (百济神州) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] - The company's stock opened at $316.0 per share, with a market capitalization of $37.43 billion as of August 15 [1] Financial Performance - As of June 30, 2025, BeiGene reported total revenue of $2.433 billion, representing a year-over-year growth of 44.73% [1] - The net profit attributable to the parent company reached $95.59 million, showing a significant increase of 125.73% compared to the previous year [1] Product Portfolio - BeiGene has a comprehensive product portfolio that includes six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - The company has also obtained licensing rights for five drugs and investigational products, including three drugs (ABRAXANE, REVLIMID, and VIDAZA) exclusively licensed from Celgene, which are already marketed in China [2]

Core Viewpoint - HHLR Advisors, a fund management platform under Hillhouse Capital, revealed its U.S. stock holdings as of the end of Q2 2025, showing a total market value of $3.10 billion, a decrease from $3.54 billion in the previous quarter, with a continued focus on Chinese stocks, particularly Pinduoduo, which remains the largest holding [2][3][5]. Holdings Summary - HHLR's U.S. stock holdings are primarily concentrated in Chinese stocks, accounting for over 90% of the portfolio, reflecting a long-term optimism towards quality Chinese assets [5][7]. - In Q2 2025, HHLR made two new purchases, added to two existing positions, sold out of 15 stocks, and reduced holdings in nine stocks [5][6]. - The top ten holdings represent 90.28% of the total portfolio, indicating a high concentration in key sectors such as internet technology, consumer goods, and biopharmaceuticals [5][6]. Major Holdings - Pinduoduo remains the largest holding with an increase of 414,200 shares, bringing the total to 6.9768 million shares, valued at $730 million, which constitutes 11.52% of the portfolio [6][7]. - Futu Holdings also saw an increase in holdings to 4.3122 million shares, valued at $533 million, with a year-to-date increase of over 118% [7]. - Webull Corporation (微牛证券) entered the top ten holdings for the first time, with 33.0808 million shares valued at $39.564 million, following its NASDAQ listing in April 2025 [7]. Reductions in Holdings - HHLR reduced its positions in Alibaba, Beike, and NetEase, selling 2.7581 million shares of Alibaba, bringing the total to 1.1497 million shares, valued at $130 million [9]. - The firm also decreased its holdings in Beike by 4.5079 million shares and in NetEase to 1.6637 million shares, reflecting a strategy to lock in profits amid rising stock prices [9]. - Other notable reductions included JD.com, Yatsen Holding, and Vipshop, with complete sell-offs of companies like Baidu and Trip.com [9].

Group 1: Market Overview - Global markets showed positive performance, with the Hang Seng Index rising by 2.58% and the Nasdaq increasing by 0.14% year-to-date [1][3] - The Hong Kong stock market experienced significant gains, particularly in healthcare, information technology, and consumer discretionary sectors, while utilities, telecommunications, and energy sectors lagged [3] - A net outflow of HKD 8.277 billion was observed from southbound funds, indicating a cautious sentiment among investors [3] Group 2: Economic Insights - The U.S. economy is experiencing a rebound in core inflation, with expectations for a potential interest rate cut being pushed to later dates [4] - China's economic indicators show a continued recovery, with M1 and M2 growth rates reaching recent highs, although household housing demand remains weak [4] - The Chinese central bank is expected to maintain a loose monetary policy, potentially lowering the reserve requirement ratio (RRR) and the loan prime rate (LPR) in the future [4][5] Group 3: Company Analysis - Tencent - Tencent reported a strong Q2 2025 performance, with total revenue and non-IFRS operating profit increasing by 15% and 18% year-on-year, respectively [5] - The gaming and marketing segments showed robust growth, with year-on-year increases of 22% and 20%, contributing to a 3.6 percentage point rise in gross margin [5] - The target price for Tencent has been raised to HKD 705.0, reflecting confidence in its growth strategy and AI development opportunities [5] Group 4: Company Analysis - Hongteng Precision - Hongteng Precision's Q2 2025 results met expectations, with revenue and net profit growing by 9% and 13% year-on-year, respectively [6] - The company is accelerating its business transformation, with AI cloud and automotive segments accounting for 36% of revenue in Q2, up from 24% in 2024 [6][7] - The target price for Hongteng Precision is set at HKD 4.96, based on a rolling 16 times 2026 expected P/E ratio, indicating an attractive valuation [7] Group 5: Company Analysis - 361 Degrees - 361 Degrees maintains its sales growth guidance of 10%-15% for FY25, supported by strong demand for basketball products and e-commerce growth [8][9] - However, there are concerns regarding store opening risks and declining same-store sales, which could impact future orders [8] - The target price for 361 Degrees has been adjusted to HKD 7.09, reflecting a valuation based on 11 times FY25 expected P/E [8]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 24,970, up 0.25% for the day and 24.48% year-to-date [1] - The US markets saw gains, with the Dow Jones up 1.10% and the S&P 500 up 1.13%, reflecting positive sentiment driven by moderate inflation data [3] Hong Kong Stock Performance - The Hang Seng Financial Index rose 0.52% and is up 28.47% year-to-date, while the Hang Seng Utilities Index fell 0.30% but is still up 5.00% for the year [2] - Southbound capital saw a net inflow of HKD 9.45 billion, indicating strong interest in Hong Kong stocks [3] Economic Policies and Impacts - The Chinese government announced targeted interest subsidies for personal consumption loans, potentially leading to an increase in loan growth by CNY 1 trillion [3] - The Hong Kong Monetary Authority intervened by buying HKD 7.065 billion to defend the currency peg, with total purchases since June reaching HKD 116.6 billion [3] Company Analysis: Kingdee International - Kingdee reported a 1H25 revenue of CNY 3.19 billion, a year-on-year increase of 11.2%, aligning with expectations [4] - The company aims for AI-related revenue to constitute over 30% of total revenue by 2030, with AI contracts exceeding CNY 150 million in 1H25 [4] Company Analysis: Tencent Music - Tencent Music's 2Q25 revenue grew 18% to CNY 8.44 billion, with Non-IFRS net profit increasing 37% to CNY 2.57 billion, surpassing market expectations [5] - The company is expected to continue its growth trajectory, with projected revenue and profit increases of 17% and 28% respectively for 3Q25 [5] Focus Stocks - Geely Automobile (175 HK) has a target price of HKD 24.00, representing a 24% upside potential [6] - Luckin Coffee (LKNCY US) has a target price of USD 44.95, indicating a 19% upside potential [6] - Tencent (700 HK) is rated "Buy" with a target price of HKD 660.00, reflecting an 18% upside potential [6]

Summary of the Conference Call for BeiGene Company Overview - **Company**: BeiGene - **Industry**: Innovative Pharmaceuticals - **Date of Call**: August 10, 2025 Key Points Company Strategy and Market Position - BeiGene is a leading innovative pharmaceutical company in China, accelerating its international strategy through independent global clinical development and commercialization [2][4] - The company has a strong pipeline with high clinical enrollment speed and quality, particularly in ADC and CDECK platform development, laying a foundation for future new molecular entities [2][4] Core Products and Financial Performance - **Zebutinib**: The core product has shown strong performance in the U.S. market, with second-quarter results exceeding expectations. Year-over-year and quarter-over-quarter growth is robust, especially in the treatment of chronic lymphocytic leukemia (CLL) [2][3] - Projected revenue for 2025 is expected to reach between $5 billion and $5.3 billion, indicating significant growth [3] - Zebutinib's peak sales potential is anticipated to exceed current levels, with a global sales figure of over $2 billion last year [13] New Product Development - In addition to Zebutinib, BeiGene is developing BCL-2 inhibitor Sotorasib and BTK inhibitor CDECK, which are expected to significantly enhance revenue [2][6] - The company is actively expanding into solid tumor areas with approved products like PD-1 and early-stage products such as CDK4, PAN-KRAS, and EGFR-CDECK, which are expected to enter clinical trials in the coming years [2][6][9] Clinical Development and Regulatory Progress - Sotorasib is expected to be approved by 2026, and the progress of BTK-CDECK in Phase III clinical trials is noteworthy [8] - Multiple catalysts for development are anticipated in the second half of the year, including the approval of Sotorasib and updates on various clinical trials [10] Market Dynamics and Competitive Landscape - BeiGene's unique position as the only domestic company conducting independent global clinical development allows it to maintain a competitive edge [4] - The company is well-positioned to navigate U.S. policy changes, including drug price negotiations and Medicare reforms, with minimal impact on its core products [7][27] Financial Projections and Valuation - Future peak sales projections include $7 to $8 billion for Zebutinib, $2.5 billion for Sotorasib, and $2 billion for BTK CDECK, with a total valuation estimate of 350 billion RMB [29] - The company is rated as a "buy" due to its potential for excess returns as a leader in Chinese innovation [29] Additional Insights - The market for chronic lymphocytic leukemia is evolving, with a shift towards targeted therapies like BTK inhibitors, which have a long treatment duration and high patient numbers [12] - Fixed-duration therapies are raising concerns about market size, but real-world studies suggest that overall healthcare costs may decrease, potentially benefiting BeiGene's sales [21] Conclusion - BeiGene is positioned for significant growth with a strong pipeline and strategic international expansion, while navigating market challenges effectively. The company's innovative approach and robust product development are expected to drive future revenue and valuation increases.

Summary of BeOne Medicines (ONC/688235.SS) Earnings Review Company Overview - BeOne Medicines is a global oncology company based in Switzerland, focusing on innovative cancer treatments, particularly in hematology and solid tumors, with key products including Brukinsa and Tevimbra [13][14]. Key Financial Highlights - **2Q Product Sales**: Achieved US$1.3 billion, a 41% year-over-year increase, surpassing expectations (GSe: US$1.23 billion) [1] - **Brukinsa Sales**: Contributed US$684 million, reflecting a 43% year-over-year growth and a 21% quarter-over-quarter increase [1] - **Tevimbra Sales**: Reported US$194 million, a 22% year-over-year increase, with strong performance in China [1] - **China Sales**: Reached US$83 million, a 31% year-over-year increase [1] Guidance and Profitability - **FY25 Guidance**: Raised from US$4.9 billion to a range of US$5.0 billion to US$5.3 billion [1] - **Net Income**: Increased to US$94 million in 2Q, compared to US$1 million in 1Q, driven by strong topline growth and a gross profit margin (GPM) of 87.4% [2] - **Operating Expenses**: SG&A expenses were US$538 million (+21% y/y), and R&D expenses were US$525 million (+15% y/y) [2] Market Position and Competitive Landscape - **Market Share**: Brukinsa continues to gain market share among BTK inhibitors, with a 38% share in the US [1][11] - **1L CLL Position**: Management expressed confidence in maintaining a strong position against competition from pirtobrutinib, citing the need for head-to-head trials for new entrants [7] Future Catalysts - **Upcoming Milestones**: Key trials and data readouts expected in the next 12 months include: - Brukinsa: Phase 3 MANGROVE trial readout in TN MCL in 2H25 - Sonrotoclax: First global registrational filing in R/R MCL in 2H25 - BTK CDAC: Phase 3 initiation in R/R CLL in 2H25 [8] Valuation and Price Target - **Earnings Estimates**: Adjusted FY2025-2027 earnings estimates to US$2.77, US$6.61, and US$8.04 respectively [9] - **Target Prices**: Updated 12-month target prices to US$378.20 for ONC and Rmb328.65 for A-share [9][14] Risks and Considerations - **Key Risks**: Include uncertainties in R&D and regulatory approvals, competition in the BTK/PD-1 space, and potential market access bottlenecks [13][14]. Conclusion - BeOne Medicines is positioned for growth with strong sales performance, raised guidance, and a robust pipeline. The company is well-placed to navigate competitive pressures and capitalize on upcoming clinical milestones [13][14].

BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.32 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 41.6%. EPS of $0.84 for the same period compares to -$1.15 a year ago.The reported revenue represents a surprise of +6.17% over the Zacks Consensus Estimate of $1.24 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +75%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...